Drug evaluation in treating postpartum hemorrhage

doi:10.3877/cma.j.issn.2095-3259.2014.04.004

Abstract

Abstract:

The most common cause of postpartum hemorrhage is uterine inertia, thus it is critical to use effective uterine contraction drugs as early as possible for the postpartum hemorrhage patients. Uterine contraction drugs can be divided into 8 categories, and oxytocin is the first-line drug, and carboprost tromethamine is the preferred second-line drug.

Key words: Postpartum hemorrhage, Uterine inertia, Drug therapy

Juan Qiao, Hongbo Qi. Drug evaluation in treating postpartum hemorrhage[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2014, 03(04): 240-243.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhckjjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3259.2014.04.004

https://zhckjjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I04/240

References 15

[1]	中华医学会妇产科学分会产科学组. 产后出血预防与处理指南(2014)[J]. 中华妇产科杂志，2014, 49(9):641-646.
[2]	World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage[R]. Geneva: World Health Organization, 2012.
[3]	American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage[J]. Obstet Gynecol, 2006, 108(4):1039-1047.
[4]	张宏秀，孙丽洲，王美莲，等. 卡贝缩宫素联合缩宫素预防阴道分娩产后出血效果分析[J]. 中国实用妇科与产科杂志，2012, 28(10):767-769.
[5]	Leduc D, Senikas V, Lalonde AB, et al. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage[J]. J Obstet Gynaecol Can, 2009, 31(10):980-993.
[6]	刘兴会，杨慧霞. 产后出血预防和处理措施评价[J]. 中华围产医学杂志，2013, 16(8):449-451.
[7]	林其德，杨孜，古航，等. 卡前列甲酯临床应用专家共识(2013年版)[J]. 中国实用妇科与产科杂志，2013, 29(6):431-433.
[8]	Franchini M, Franchi M, Bergamini V, et al. The use of recombinant activated FⅦ in postpartum hemorrhage[J]. Clin Obstet Gynecol, 2010, 53(1):219-227.
[9]	Kobayashi T, Nakabayashi M, Yoshioka A, et al. Recombinant activated factor Ⅶ rF Ⅶa/Novoseven in the management of severe postpartum haemorrhage：initial report of a multicentre case series in Japan[J]. Int J Hematol, 2012, 95(1):57-63.
[10]	Welsh A, McLintock C, Gatt S, et al. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage[J]. Aust N Z J Obstet Gynaecol, 2008, 48(1):12-16.
[11]	陈敦金，刘晓燕. 产后出血休克的A/B/C/D/E管理[J]. 广东医学，2010, 31(17):2196-2197.
[12]	温兰英，张桂芬，齐爱英. 垂体后叶素预防产后出血200例临床分析[J]. 中国现代药物应用，2008, 2(16):75-76.
[13]	Gai MY, Wu LF, Su QF, et al. Clinical observation of blood loss reduced by tranexamic acid during and after caesaren section：a multicenter randomized trial[J]. Eur J Obstet Gynecol Reprod Biol, 2004, 112(2):154-157.
[14]	杨慧霞，郑淑蓉，时春艳，等. 氨甲环酸用于减少产后出血量的临床研究[J]. 中华妇产科杂志，2001, 36(10):590-592.
[15]	陈健，陆晓明，郭秀云，等. 产时补钙防治宫缩乏力性产后出血的临床对比观察[J]. 中国实用妇科与产科杂志，2004, 20(10):635-636.

Please choose a citation manager

Content to export